Lowering effects of four different statins on serum triglyceride level

European Journal of Clinical Pharmacology

Volumn 55, Issue 7, 1999, Pages 499-502

  Branchi, A ^a   Fiorenza, A M ^b   Rovellini, A ^a   Torri, A ^b   Muzio, F ^b   Macor, S ^b   Sommariva, D ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b RHO HOSPITAL   (Italy)

Author keywords

Cholesterol; Low density lipoprotein; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGRESSION ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0032857468     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050663     Document Type: Article

References (21)

1. Illingworth DR (1991) HMG CoA reductase inhibitors. Curr Opin Lipidol 2: 24-30
2. Endo A (1992) The discovery and development of HMG CoA reductase inhibitors. J Lipid Res 33: 1569-1582
3. Beisiegel U (1998) Lipoprotein metabolism. Eur Heart J 19[suppl A]: A20-A23
4. Plosker GL, McTavish D (1995) Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs 50: 334-363
5. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber HE, Black DM (1995) Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-COA reductase inhibitor. Arterioscler Thromb Vasc Biol 15: 678-682
6. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Issacshon JL, Weiss SR, Keilson LM, Brown V, Miller VT, Shurzinske LJ, Black DM (1996) Efficacy and safety of a new HMG-COA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275: 128-133
7. Branchi A, Rovellini A, Fiorenza AM, Maraffi F, Gandini R, Sommariva D (1996) The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level. Int J Clin Pharmacol Ther 34: 384-389
8. Stein EA, Lane M, Laskarzewski P (1998) Comparison of statins in hypertriglyceridemia. Am J Cardiol 81: 66B-69B
9. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves Study). Am J Cardiol 81: 582-587
10. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth DR, Knopp RH, Miller VT, Frost P, Isaacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tobert JA (1996) Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther 1: 107-116
11. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Braes P, Black D (1997) A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 80: 39-44
12. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease (1993) NIH consensus conference: triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 269: 505-510
13. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based studies. J Cardiovasc Risk 3: 213-219
14. Krauss RM (1998) Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med 105: 48S-62S
15. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultra centrifuge. Clin Chem 18: 499-502
16. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ (1984) Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 74: 470-482
17. Sommariva D, Branchi A, Tirrito M, Bonfiglioli D, Pini C, Scandiani L, Ottomano C, Fasoli A (1988) Relationship of serum triglyceride concentration to lipoprotein composition and concentration in normolipidemic and hyperlipidemic subjects. Res Clin Lab 18: 281-290
18. Vega GL, Grundy SM (1990) Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. JAMA 264: 2759-2763
19. Vega GL, Grundy SM (1990) Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med 150: 1313-1319
20. Arad Y, Ramakrishnan R, Ginsberg H (1992) Effects of lovastatin on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41: 487-493
21. Huff MW, Burnett JR (1997) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol 8: 138-145